Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.59
SCMP's Cash to Debt is ranked lower than
69% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. SCMP: 0.59 )
Ranked among companies with meaningful Cash to Debt only.
SCMP' s Cash to Debt Range Over the Past 10 Years
Min: 0.43  Med: 13.52 Max: No Debt
Current: 0.59
Equity to Asset 0.32
SCMP's Equity to Asset is ranked lower than
86% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.65 vs. SCMP: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
SCMP' s Equity to Asset Range Over the Past 10 Years
Min: -0.21  Med: 0.49 Max: 0.82
Current: 0.32
-0.21
0.82
Interest Coverage 1.32
SCMP's Interest Coverage is ranked lower than
94% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.40 vs. SCMP: 1.32 )
Ranked among companies with meaningful Interest Coverage only.
SCMP' s Interest Coverage Range Over the Past 10 Years
Min: 1.32  Med: 90.98 Max: No Debt
Current: 1.32
F-Score: 5
Z-Score: 2.66
M-Score: 1.32
WACC vs ROIC
10.15%
14.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 15.04
SCMP's Operating margin (%) is ranked higher than
70% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. SCMP: 15.04 )
Ranked among companies with meaningful Operating margin (%) only.
SCMP' s Operating margin (%) Range Over the Past 10 Years
Min: -32.3  Med: 17.01 Max: 29.02
Current: 15.04
-32.3
29.02
Net-margin (%) 6.29
SCMP's Net-margin (%) is ranked higher than
53% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.71 vs. SCMP: 6.29 )
Ranked among companies with meaningful Net-margin (%) only.
SCMP' s Net-margin (%) Range Over the Past 10 Years
Min: -31.6  Med: 9.6 Max: 41.39
Current: 6.29
-31.6
41.39
ROE (%) 11.64
SCMP's ROE (%) is ranked higher than
66% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.47 vs. SCMP: 11.64 )
Ranked among companies with meaningful ROE (%) only.
SCMP' s ROE (%) Range Over the Past 10 Years
Min: -37.45  Med: 16.17 Max: 154.11
Current: 11.64
-37.45
154.11
ROA (%) 3.32
SCMP's ROA (%) is ranked lower than
51% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. SCMP: 3.32 )
Ranked among companies with meaningful ROA (%) only.
SCMP' s ROA (%) Range Over the Past 10 Years
Min: -11.28  Med: 7.37 Max: 37.89
Current: 3.32
-11.28
37.89
ROC (Joel Greenblatt) (%) 61.94
SCMP's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. SCMP: 61.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SCMP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -138.06  Med: 117.54 Max: 6536.15
Current: 61.94
-138.06
6536.15
Revenue Growth (3Y)(%) 19.80
SCMP's Revenue Growth (3Y)(%) is ranked higher than
83% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. SCMP: 19.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SCMP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.2  Med: 19.8 Max: 128.6
Current: 19.8
-21.2
128.6
EBITDA Growth (3Y)(%) 67.80
SCMP's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.50 vs. SCMP: 67.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SCMP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.8  Med: 35.75 Max: 206.8
Current: 67.8
-19.8
206.8
EPS Growth (3Y)(%) 82.50
SCMP's EPS Growth (3Y)(%) is ranked higher than
95% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. SCMP: 82.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SCMP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.3  Med: -20.6 Max: 82.5
Current: 82.5
-56.3
82.5
» SCMP's 10-Y Financials

Financials (Next Earnings Date: 2017-03-08)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

SCMP Guru Trades in Q4 2015

Joel Greenblatt 583,716 sh (+273.69%)
Jim Simons 554,800 sh (+25.49%)
Paul Tudor Jones 31,008 sh (-33.92%)
» More
Q1 2016

SCMP Guru Trades in Q1 2016

Chuck Royce 17,459 sh (New)
Jim Simons 825,700 sh (+48.83%)
Paul Tudor Jones 43,846 sh (+41.40%)
Joel Greenblatt 284,704 sh (-51.23%)
» More
Q2 2016

SCMP Guru Trades in Q2 2016

Chuck Royce 367,516 sh (+2005.02%)
Jim Simons 1,107,700 sh (+34.15%)
Joel Greenblatt Sold Out
Paul Tudor Jones 18,000 sh (-58.95%)
» More
Q3 2016

SCMP Guru Trades in Q3 2016

Steven Cohen 171,600 sh (New)
Chuck Royce 556,313 sh (+51.37%)
Jim Simons 1,353,000 sh (+22.14%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SCMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)


Warning: mysql_num_rows() expects parameter 1 to be resource, boolean given in /home/gurufocu/public_html/modules/stock/gurutrades_morn.php on line 187
No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:HRTX, OTCPK:EVTCY, OTCPK:NPPNY, NYSE:LCI, NAS:ACET, NAS:SCLN, NAS:FLXN, NAS:AMPH, NAS:COLL, NAS:SGYP, NYSE:DPLO, NAS:MNTA, OTCPK:KHTRF, NAS:KPTI, NAS:ADMS, NAS:AQXP, NAS:IPXL, NAS:SUPN, NAS:ARLZ, NAS:RIGL » details
Traded in other countries:R3A.Germany,
Sucampo Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in research & development of proprietary drugs based on ion channel activators known as prostones to treat gastrointestinal, neurologic, & oncology-based inflammatory disorders.

Sucampo Pharmaceuticals Inc was incorporated on 05 December 1996. The Company is a biopharmaceutical company engaged in research, discovery, development and commercialization of proprietary drugs based on ion channel activators known as prostones. The Company is engaged in developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and also considering other potential therapeutic applications of its drug technologies. It generates revenue primarily from product royalties, development milestone payments, clinical development activities and product sales. The Company seeks additional regulatory approvals and additional indications for AMITIZA (lubiprostone), RESCULA (unoprostone isopropyl) and other compounds. Its operations are conducted through subsidiaries based in Japan, the United States, Switzerland, the United Kingdom and Luxembourg. Its reportable geographic segments are Asia, the Americas and Europe. The Company has over 525 active issued patents based on its proprietary prostone technology. It holds all commercialization rights for unoprostone isopropyl except for Japan, Korea, Taiwan and the People's Republic of China.

Ratios

vs
industry
vs
history
P/E(ttm) 53.26
SCMP's P/E(ttm) is ranked lower than
78% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.64 vs. SCMP: 53.26 )
Ranked among companies with meaningful P/E(ttm) only.
SCMP' s P/E(ttm) Range Over the Past 10 Years
Min: 5.52  Med: 27.27 Max: 105.44
Current: 53.26
5.52
105.44
Forward P/E 10.60
SCMP's Forward P/E is ranked higher than
82% of the 94 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.71 vs. SCMP: 10.60 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 53.26
SCMP's PE(NRI) is ranked lower than
77% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.23 vs. SCMP: 53.26 )
Ranked among companies with meaningful PE(NRI) only.
SCMP' s PE(NRI) Range Over the Past 10 Years
Min: 5.52  Med: 27.27 Max: 105.44
Current: 53.26
5.52
105.44
Price/Owner Earnings (ttm) 16.86
SCMP's Price/Owner Earnings (ttm) is ranked higher than
77% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.83 vs. SCMP: 16.86 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SCMP' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.46  Med: 37.18 Max: 2344
Current: 16.86
10.46
2344
P/B 4.85
SCMP's P/B is ranked lower than
74% of the 953 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. SCMP: 4.85 )
Ranked among companies with meaningful P/B only.
SCMP' s P/B Range Over the Past 10 Years
Min: 0.97  Med: 4.69 Max: 11.83
Current: 4.85
0.97
11.83
P/S 3.21
SCMP's P/S is ranked lower than
54% of the 881 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.91 vs. SCMP: 3.21 )
Ranked among companies with meaningful P/S only.
SCMP' s P/S Range Over the Past 10 Years
Min: 1.2  Med: 3.12 Max: 9.54
Current: 3.21
1.2
9.54
PFCF 32.02
SCMP's PFCF is ranked lower than
64% of the 270 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.85 vs. SCMP: 32.02 )
Ranked among companies with meaningful PFCF only.
SCMP' s PFCF Range Over the Past 10 Years
Min: 3.67  Med: 27.1 Max: 376.52
Current: 32.02
3.67
376.52
POCF 26.33
SCMP's POCF is ranked lower than
69% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.38 vs. SCMP: 26.33 )
Ranked among companies with meaningful POCF only.
SCMP' s POCF Range Over the Past 10 Years
Min: 3.62  Med: 27.02 Max: 161.87
Current: 26.33
3.62
161.87
EV-to-EBIT 19.36
SCMP's EV-to-EBIT is ranked lower than
51% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.57 vs. SCMP: 19.36 )
Ranked among companies with meaningful EV-to-EBIT only.
SCMP' s EV-to-EBIT Range Over the Past 10 Years
Min: -2724.9  Med: 12.05 Max: 51.3
Current: 19.36
-2724.9
51.3
EV-to-EBITDA 8.93
SCMP's EV-to-EBITDA is ranked higher than
77% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. SCMP: 8.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
SCMP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -746  Med: 8.7 Max: 193.6
Current: 8.93
-746
193.6
Shiller P/E 66.05
SCMP's Shiller P/E is ranked lower than
66% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.34 vs. SCMP: 66.05 )
Ranked among companies with meaningful Shiller P/E only.
SCMP' s Shiller P/E Range Over the Past 10 Years
Min: 39.76  Med: 57.65 Max: 2109
Current: 66.05
39.76
2109
Current Ratio 3.55
SCMP's Current Ratio is ranked higher than
67% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. SCMP: 3.55 )
Ranked among companies with meaningful Current Ratio only.
SCMP' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.6 Max: 9.21
Current: 3.55
1.27
9.21
Quick Ratio 3.19
SCMP's Quick Ratio is ranked higher than
70% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. SCMP: 3.19 )
Ranked among companies with meaningful Quick Ratio only.
SCMP' s Quick Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.57 Max: 9.21
Current: 3.19
1.27
9.21
Days Inventory 97.79
SCMP's Days Inventory is ranked higher than
60% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.87 vs. SCMP: 97.79 )
Ranked among companies with meaningful Days Inventory only.
SCMP' s Days Inventory Range Over the Past 10 Years
Min: 2.34  Med: 3.08 Max: 164.56
Current: 97.79
2.34
164.56
Days Sales Outstanding 35.54
SCMP's Days Sales Outstanding is ranked higher than
84% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.59 vs. SCMP: 35.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCMP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.75  Med: 13.77 Max: 54.23
Current: 35.54
1.75
54.23
Days Payable 37.13
SCMP's Days Payable is ranked lower than
81% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.65 vs. SCMP: 37.13 )
Ranked among companies with meaningful Days Payable only.
SCMP' s Days Payable Range Over the Past 10 Years
Min: 9.38  Med: 92.95 Max: 662.06
Current: 37.13
9.38
662.06

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.70
SCMP's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 434 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.70 vs. SCMP: -2.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SCMP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.6  Med: -0.1 Max: 0
Current: -2.7
-9.6
0

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.65
SCMP's Price/Projected FCF is ranked higher than
51% of the 416 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. SCMP: 2.65 )
Ranked among companies with meaningful Price/Projected FCF only.
SCMP' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.93  Med: 3.55 Max: 46
Current: 2.65
0.93
46
Price/Median PS Value 1.02
SCMP's Price/Median PS Value is ranked higher than
57% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. SCMP: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
SCMP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.69  Med: 1.03 Max: 2.33
Current: 1.02
0.69
2.33
Earnings Yield (Greenblatt) (%) 5.13
SCMP's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 1015 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. SCMP: 5.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SCMP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2  Med: 6.1 Max: 128.9
Current: 5.13
2
128.9

More Statistics

Revenue (TTM) (Mil) $212.4
EPS (TTM) $ 0.29
Beta1.22
Short Percentage of Float9.13%
52-Week Range $9.59 - 18.75
Shares Outstanding (Mil)45.84

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 221 236 253 277
EPS ($) 0.85 1.39 1.56 1.58
EPS w/o NRI ($) 0.85 1.39 1.56 1.58
EPS Growth Rate
(3Y to 5Y Estimate)
97.00%
Dividends Per Share ($)
» More Articles for SCMP

Headlines

Articles On GuruFocus.com
NeoPhotonics Delivers Sustained Profitability; Gevo Continues Biofuel Deal Momentum May 08 2015 
Pharmaceutical Stock Picks For March Mar 04 2015 
Weekly CEO Sells Highlight: VeriFone Systems Inc, Northeast Utilities, Sucampo Pharmaceuticals Inc, Jan 26 2014 
Weekly CEO Sells Highlight: Sucampo Pharmaceuticals Inc, Family Dollar Stores Inc, Nike Inc, Hallibu Oct 21 2013 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 08 2011 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 06 2009 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
Heat Biologics Stock Falls on Negative Bladder Cancer Data Dec 01 2016
Cytori Scleroderma Study Two-Year Follow-Up Data Published Nov 30 2016
PhaseRx Soars on Orphan Drug Status for Rare Liver Disease Nov 30 2016
Zacks.com featured highlights: Chimera Investment, PennyMac Financial Services and Sucampo... Nov 30 2016
Sucampo (SCMP) Worth a Look: Stock Jumps 6.2% in Session Nov 30 2016
Stocks Stay Red As Gold, Oil Prices Rise; Amazon, Building Stocks Weigh Nov 28 2016
Trump-Tied Plays Dip; Under Armour Up On Ticker Switch Nov 28 2016
What You Need To Know For Your Week: Top 3 Earnings On Tap Nov 25 2016
Stocks End Thanksgiving Week With Modest Gains; Oil Slumps 3% Nov 25 2016
Looking for a Growth Stock? Why it is Time to Focus on Sucampo Pharmaceuticals (SCMP) Nov 25 2016
Glaxo Nucala Favorable in Rare Vasculitis Disease Study Nov 24 2016
Why Sucampo Pharmaceuticals (SCMP) Could Be Positioned for a Surge Nov 23 2016
Bristol-Myers' Opdivo Gets EU Approval for Label Expansion Nov 23 2016
Zacks.com featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, VMware and Alexandria Real... Nov 22 2016
Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18,... Nov 18 2016
SUCAMPO PHARMACEUTICALS, INC. Financials Nov 17 2016
Zacks.com featured highlights: Lancaster Colony, Foot Locker, ULTA Salon, Cosmetics & Fragrance,... Nov 17 2016
5 Top Stocks to Buy with Stellar Earnings Growth Nov 16 2016
Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US :... Nov 11 2016
Sucampo (SCMP) Beats Q3 Earnings & Revenues, Guides Up Nov 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)